GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
You may also be interested in...
The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.
Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.
Sanofi is beefing up its investment in mRNA vaccine technology with a €400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.